Dimercaptosuccinic acid for the treatment of hyperhomocysteinemia in hemodialysis patients: A placebo-controlled, double-blind, randomized trial

American Journal of Kidney Diseases

Volumn 44, Issue 4, 2004, Pages 689-694

  House, Andrew A ^a,b,c   Eliasziw, Michael ^e   Urquhart, Bradley L ^a   Freeman, David J ^a,b   Spence, J David ^a,d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

^d ROBARTS RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

cardiovascular; dimercaptosuccinic acid (DMSA); hemodialysis (HD); Homocysteine; randomized controlled study

Indexed keywords

HOMOCYSTEINE; MULTIVITAMIN; SUCCIMER; VITAMIN;

ADULT; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SOLUBILITY; FEMALE; HEMODIALYSIS; HUMAN; HYPERCHROMOCYSTEINEMIA; INTERMETHOD COMPARISON; KIDNEY DISEASE; LONG TERM CARE; MALE; MULTIVARIATE ANALYSIS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; CARDIOVASCULAR DISEASES; CHELATING AGENTS; DOUBLE-BLIND METHOD; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RISK FACTORS; SUCCIMER; VITAMINS;

EID: 4544302945     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2004.06.010     Document Type: Article

References (27)

1. G.N. Welch, J. Loscalzo Homocysteine and atherothrombosis N Engl J Med 338 1998 1042 1050
2. A.G. Bostom, L. Lathrop Hyperhomocysteinemia in end-stage renal disease Prevalence, etiology, and potential relationship to arteriosclerotic outcomes Kidney Int 52 1997 10 20
3. V.W. Dennis, K. Robinson Homocysteinemia and vascular disease in end-stage renal disease Kidney Int Suppl 57 1996 S11 S17
4. M. Födinger, C. Mannhalter, G. Wölfl Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients Kidney Int 52 1997 517 523
5. S.H. Mudd, J.D. Finkelstein, H. Refsum Homocysteine and its disulfide derivatives A suggested consensus terminology Arterioscler Thromb Vasc Biol 20 2000 1704 1706
6. A.G. Bostom, R.Y. Gohh, M.Y. Tsai Excess prevalence of fasting and postmethionine-loading hyperhomocysteinemia in stable renal transplant recipients Arterioscler Thromb Vasc Biol 17 1997 1894 1900
7. A.G. Bostom, D. Shemin, K.L. Lapane Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients Atherosclerosis 123 1996 193 202
8. A.G. Bostom, D. Shemin, K.L. Lapane Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein(a) excess in maintenance dialysis patients A matched case-control study Atherosclerosis 125 1996 91 101
9. A.A. House, J.G. Donnelly Effect of multivitamins on plasma homocysteine and folate levels in patients on hemodialysis ASAIO J 45 1999 94 97
10. A.A. House, G.A. Wells, J.G. Donnelly, S.P. Nadler, P.C. Hebert Randomized trial of high-flux vs low-flux haemodialysis Effects on homocysteine and lipids Nephrol Dial Transplant 15 2000 1029 1034
11. T. Tamura, K.E. Johnston, S.M. Bergman Homocysteine and folate concentrations in blood from patients treated with hemodialysis J Am Soc Nephrol 7 1996 2414 2418
12. J.M. Gonin, H. Nguyen, R. Gonin Controlled trials of very high dose folic acid, vitamins J Nephrol 16 2003 522 524
13. A. Yango, D. Shemin, N. Hsu Rapid communication l-Folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients Kidney Int 59 2001 324 327
14. A.G. Bostom, D. Shemin, K.L. Lapane Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis A case-control study Atherosclerosis 114 1995 93 103
15. A.G. Bostom, D. Shemin, M.R. Nadeau Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementation Atherosclerosis 113 1995 129 132
16. A.G. Bostom, D. Shemin, K.L. Lapane High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients Kidney Int 49 1996 147 152
17. E. Friedheim, J.H. Graziano, D. Popovac, D. Dragovic, B. Kaul Treatment of lead poisoning by 2,3-dimercaptosuccinic acid Lancet 2 1978 1234 1236
18. R.M. Maiorino, M.M. Aposhian, Z.F. Xu, Y. Li, R.L. Polt, H.V. Aposhian Determination and metabolism of dithiol chelating agents XV. The meso-2,3-dimercaptosuccinic acid-cysteine (1:2) mixed disulfide, a major urinary metabolite of DMSA in the human, increases the urinary excretion of lead in the rat J Pharmacol Exp Ther 267 1993 1221 1226
19. P.J. Kostyniak Methylmercury removal in the dog during infusion of 2,3-dimercaptosuccinic acid (DMSA) J Toxicol Environ Health 11 1983 947 957
20. P.J. Kostyniak, H.B. Greizerstein, J. Goldstein Extracorporeal regional complexing haemodialysis treatment of acute inorganic mercury intoxication Hum Exp Toxicol 9 1990 137 141
21. D.W. Jacobsen, V.J. Gatautis, R. Green Rapid HPLC determination of total homocysteine and other thiols in serum and plasma Sex differences and correlation with cobalamin and folate concentrations in healthy subjects Clin Chem 40 1994 873 881
22. D. Shemin, K.L. Lapane, L. Bausserman Plasma total homocysteine and hemodialysis access thrombosis A prospective study J Am Soc Nephrol 10 1999 1095 1099
23. A. Moustapha, A. Naso, M. Nahlawi Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease Circulation 97 1998 138 141
24. L.M. Friedman, C.D. Furberg, D.L. DeMets Fundamentals of Clinical Trials (ed 3) 1996 Mosby St Louis, MO 94 129
25. E.M. Wrone, J.M. Hornberger, J.L. Zehnder, L.M. McCann, N.S. Coplon, S.P. Fortmann Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease J Am Soc Nephrol 15 2004 420 426
26. A.N. Friedman, A.G. Bostom, P. Laliberty, J. Selhub, D. Shemin The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis A randomized, controlled study Am J Kidney Dis 41 2003 442 446
27. A. Scholze, C. Rinder, J. Beige, R. Riezler, W. Zidek, M. Tepel Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure Circulation 109 2004 369 374